Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma

Cancer Research

Volumn 61, Issue 20, 2001, Pages 7563-7567

  Tatsumi, Tomohide ^a   Takehara, Tetsuo ^a   Kanto, Tatsuya ^a   Hori, Masatsugu ^a   Miyagi, Takuya ^a   Kuzushita, Noriyoshi ^a   Sugimoto, Yoshiko ^a   Jinushi, Masahisa ^a   Sasaki, Yutaka ^a   Hayashi, Norio ^a,a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL LYSATE; CONTROLLED STUDY; CYTOLYSIS; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR REGRESSION;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DRUG SYNERGISM; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0035887149     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma
2. Postresection recurrence of hepatocellular carcinoma treated by arterial embolizadon: Analysis of prognostic factors
3. Percutaneous ethanol injection therapy for hepatocellular carcinoma: Results in 146 patients
4. The dendritic cell system and its role in immunogenicity
5. Dendritic cells: Unique leukocyte populations which control the primary immune response
6. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells
7. + T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens
8. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune response in vitro and in vivo
9. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccine
10. Induction of antitumor immunity using bone marrow-generated dendritic cells
11. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptide elicits protective and therapeutic antitumor immunity
12. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
13. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
14. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells
15. DNA-based immunization by in vivo transfection of dendritic cells
16. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
17. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
18. Identification and purification of natural killer cell stimulatory factors (NKSF), a cytokine with multiple biological effects on human lymphocytes
19. Responses of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): Cytolytic activity and proliferation of NK cells are differentially regulated by NKSF
20. Regulation of human cytolytic lymphocyte responses by interleukin-12
21. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune response and inhibits the development of IL-4-producing Th cells
22. Interleukin-12 and its role in generation of TH1 cells
23. IL-12 increases CD80 expression and the stimulatory capacity of bone marrow-derived dendritic cells
24. IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL response in vitro
25. Generation of large number of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colon-stimulating factor
26. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
27. Functional heterogeneity among bone marrow-derived dendritic cells conditioned by T(h)I- and T(h)2-biasing cytokines for the generation of allogeneic cytotoxic T lymphocytes
28. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes